Martinez / Castro / Medina Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors

Drug Discovery and Development
1. Auflage 2006
ISBN: 978-0-470-05215-0
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 384 Seiten, E-Book

Reihe: Wiley series in drug discovery and development

Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It's a great reference for researchers in drug design and development.

Autoren/Hrsg.

Martinez, Ana

Castro, Ana

Medina, Miguel

Weitere Mitwirkende

Wang, Binghe

Inhaltsverzeichnis

Foreword: The Origins of GSK-3.Preface.Acknowledgments.Contributors.Abbreviations. PART I: CELLULAR FUNCTIONS OF GSK-3.1. Glycogen Synthase Kinase-3 - an Introductory Synopsis .2. Glycogen-Synthase-Kinase-beta (GSK-3beta) a Key Signaling Enzyme: A Developmental Neurobiological Perspective.3. Role of GSK3/Shaggy in neuronal cell biology.4. The Crystal Structures of Glycogen Synthase Kinase 3.5. Kinase-Kinase and Site-Site Interactions in the Phosphorylation of Tau by GSK-3.PART II: GSK3 AS A THERAPEUTIC TARGET IN HUMAN PATHOLOGY.6. GSK-3, a Key Player in Alzheimer's Disease.7. Glycogen Synthase Kinase-3: A Target for Novel Mood Disorder Treatments.8. GSK3 and Stem Cells.9. Glycogen Synthase Kinase-3: role in Neurodegeneration and Neuroprotection.10. Protein Kinase Inhibitors. Assay Development.11. Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies.PART III: GSK-3 INHIBITORS: DEVELOPMENT AND THERAPEUTIC POTENTIAL.12. Lithium, the Seminal GSK3 Inhibitor.13. Inhibition of GSK3 as Therapeutic Strategy in Disease: Efficacy of AR-A014418.14. TDZD's: Selective And ATP Non Competitive Glycogen Synthase Kinase-3 Inhibitors.15. 3-Amino Pyrazoles as Potent and Selective Glycogen Synthase (GSK-3) Inhibitors.16. Marine compounds as a new source for Glycogen Synthase Kinase-3 Inhibitors.Index.

Über Autor(innen)

ANA MARTINEZ is the Research and Development Director forNeuroPharma. She has been and still is an active researcher in thedesign and synthesis of GSK-3 inhibitors.
ANA CASTRO is the Medicinal Chemistry Director ofNeuroPharma. She was formerly a tenured scientist at the MedicinalChemistry Institute.
MIGUEL MEDINA is the Drug Discovery Director atNeuroPharma. He was formerly an instructor at the Brigham andWomen's Hospital and the Harvard Medical School.